ArticleBiosensors2023
A D-Shaped Polymer Optical Fiber Surface Plasmon Resonance Biosensor for Breast Cancer Detection Applications.
Article in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Quantifying HER-2 for Precision Oncology: The Role of Optical Biosensors.Molecular biotechnology · 2026Review
- Quantifying HER-2 for Precision Oncology: The Role of Optical Biosensors.Molecular biotechnology · 2026Review
- Review
- Toscana Virus Diagnosis via a Point-of-Care Tool Based on Disposable Optical Fiber Biosensors.Analytical chemistry · 2026Article
- Overview of Optical Fiber Biosensors for the Detection of Cancer Biomarkers in the Past Decade.ACS omega · 2026Review
- Evanescent wave-based optical biosensors for innovations, medical application and future perspectives.Journal of advanced research · 2026Review
- Nanoplasmonic optical fiber sensing of SARS-CoV-2 nucleocapsid protein using an aptamer-DNA tetrahedron interface.Journal of nanobiotechnology · 2026Article
- Theoretical Investigation of Early Cancer Biomarker Sensing Using a PMMA-Gold Hybrid Quasi-D-Shaped Photonic-Crystal-Fiber-Based Surface Plasmon Resonance Biosensor.Micromachines · 2025Article
- Functionalization Techniques Empowering Optical Fiber Biosensors in Label-Free Cancer Biomarker Detection.Biosensors · 2025Review
- Tapered Optical Fiber Optofluidics: Bridging In-Fiber and Outside-Fiber Architectures Toward Autonomous Lab-on-Fiber Biosensing.Sensors (Basel, Switzerland) · 2025Review
- Plasmonic optical fiber biosensors for ultra-low detection of respiratory syncytial virus via point-of-care tests.Scientific reports · 2025Article
- Sensitivity Enhancement of Polymer Optical Fiber Surface Plasmon Resonance Sensor Utilizing ITO Overlayer.Sensors (Basel, Switzerland) · 2025Article
- Breaking barriers in cancer diagnosis: unveiling the 4Ms of biosensors.RSC advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
Fiber-optic biosensors have garnered significant attention and witnessed rapid development in recent years owing to their remarkable attributes such as high sensitivity, immunity to electromagnetic interference, and real-time monitoring. They have emerged as a potential tool in the realm of biomarker detection for low-concentration and small molecules. In this paper, a portable and cost-effective optical fiber biosensor based on surface plasmon resonance for the early detection of breast cancer is demonstrated. By utilizing the aptamer human epidermal growth factor receptor 2 (HER2) as a specific biomarker for breast cancer, the presence of the HER2 protein can be detected through an antigen-antibody binding technique. The detection method was accomplished by modifying a layer of HER2 aptamer on the flat surface of a gold-coated D-shaped polymer optical fiber (core/cladding diameter 120/490 μm), of which the residual thickness after side-polishing was about 245 μm, the thickness of the coated gold layer was 50 nm, and the initial wavelength in pure water was around 1200 nm. For low-concentration detection of the HER2 protein, the device exhibited a wavelength shift of ~1.37 nm with a concentration of 1 μg/mL (e.g., 5.5 nM), which corresponded to a limit of detection of ~5.28 nM. Notably, the response time of the biosensor was measured to be as fast as 5 s. The proposed biosensor exhibits the potential for early detection of HER2 protein in initial cancer serum and offers a pathway to early prevention of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.